Impact of Empagliflozin on Subclinical Left Ventricular Dysfunctions and on the Mechanisms Involved in Myocardial Disease Progression in Type 2 Diabetes: Rationale and Design of the Empa-Heart Trial

AuthID
P-015-CM7
5
Author(s)
Nesti L.
·
Fabiani I.
·
Calogero E.
·
Di Bello V.
Tipo de Documento
Article
Year published
2017
Publicado
in Cardiovascular Diabetology
Volume: 16, Número: 1
Indexing
Publication Identifiers
Pubmed: 29025406
SCOPUS: 2-s2.0-85030834144
Export Publication Metadata
Info
At this moment we don't have any links to full text documens.